Opko Health, Inc. (NYSE:OPK)

CAPS Rating: 3 out of 5

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

0
Member Avatar SullyUK79 (< 20) Submitted: 4/13/2016 1:42:02 PM : Outperform Start Price: $10.90 OPK Score: -0.79

Believer in Frost, FDA should ultimately approve kidney drug, recent acquisitions make sense.

Recs

0
Member Avatar Jordrok (98.84) Submitted: 2/23/2016 11:59:48 AM : Outperform Start Price: $8.94 OPK Score: +13.24

Revenues are growing and the CEO owns many shares.

Recs

0
Member Avatar genedom (97.29) Submitted: 2/4/2016 5:02:01 PM : Outperform Start Price: $8.44 OPK Score: +19.34

A value play and CEO is buying

Recs

1
Member Avatar TheBigFinn (< 20) Submitted: 10/4/2015 4:25:50 AM : Outperform Start Price: $9.14 OPK Score: +12.59

Their 4KScore Test accurately predicts prostate cancer risk has received insurance classification

Their drug Rayaldee with a +$10B market potential completed phase 3 trials and an NDA was submitted to to the FDA last May we approval expect in 2016.

Their CEO, Dr. Frost, is a consistent buyer of the stock, owns ~50% of the shares, and increased his buying as the price fell in the great BioPharma sell off of 2015

Recs

0
Member Avatar 401ktimer1 (95.84) Submitted: 8/4/2015 12:57:48 PM : Outperform Start Price: $16.13 OPK Score: -31.88

http://us.rd.yahoo.com/finance/external/forbes/SIG=12feehiff/*http://www.forbes.com/sites/genemarcial/2015/07/23/opkos-prostate-cancer-hit/?utm_campaign=yahootix&partner=yahootix

Recs

1
Member Avatar kkconway (99.34) Submitted: 7/14/2015 10:57:35 AM : Outperform Start Price: $16.56 OPK Score: -33.08

Thompson/Reuters confirmed that CEO and several insiders are buying shares like mad; millions of dollars worth in the past several months. Next quarter's positive earnings surprise, or some major announcement may be in the offing.

Recs

0
Member Avatar EnigmaDude (52.12) Submitted: 6/16/2015 11:48:43 AM : Outperform Start Price: $15.46 OPK Score: -28.89

Insiders still buying shares like mad, and recent acquisitions should add to the long term profitability.

Recs

0
Member Avatar manirg (< 20) Submitted: 5/29/2015 11:08:39 AM : Outperform Start Price: $17.63 OPK Score: -36.72

undervalued

Recs

0
Member Avatar claylew (< 20) Submitted: 5/12/2015 11:35:18 PM : Outperform Start Price: $14.69 OPK Score: -24.85

outperform

Recs

1
Member Avatar km00nster (< 20) Submitted: 3/5/2015 12:18:32 AM : Outperform Start Price: $6.92 OPK Score: +24.98

With over a 50 percent of inside ownership, a CEO that has been buying head over heals on a monthly bases and is known for successfully leading and selling many pharma companies. I believe OPK will go up further and will be a takeout target in the future. Not to mention there recent agreement with Pfizer on their Long-Acting Human Growth Hormone (hGH-CTP) drug.

Recs

0
Member Avatar hopefull1013 (< 20) Submitted: 2/23/2015 10:03:09 PM : Outperform Start Price: $14.69 OPK Score: -24.55

Dr frost!

Recs

0
Member Avatar Bauer27 (< 20) Submitted: 2/9/2015 10:07:59 AM : Outperform Start Price: $14.32 OPK Score: -25.52

They are exploring new technologies to treat diseases and diagnose diseases which are currently limited.

Recs

0
Member Avatar BEMWVL (< 20) Submitted: 1/13/2015 11:05:36 AM : Outperform Start Price: $10.38 OPK Score: +2.88

Phil Frost is a very astute investor in pharmaceutical products.

Recs

1
Member Avatar allstar31 (99.85) Submitted: 9/12/2014 11:17:00 PM : Underperform Start Price: $8.64 OPK Score: -20.82

Uses known stock promoter Redchip.com. Is a pump and dump scam.

Recs

0
Member Avatar TTime0917 (< 20) Submitted: 6/19/2014 7:44:17 AM : Outperform Start Price: $9.29 OPK Score: +10.68

I like the up-look color and diversity of products both in the near and those in the pipeline. No one can argue the success nor the brilliance of Dr. Frost.

Recs

0
Member Avatar jjiijjii (< 20) Submitted: 4/30/2014 8:37:19 AM : Outperform Start Price: $8.20 OPK Score: +21.02

Outperform over the next 5 years. I hold a small position on this one as a bet on Phillip Frost continuing the home runs he hit in the past. He ran two other small pharmas in the past, which he built into successful companies and sold at nice profits. At $8.31 per share, my investment is so small, I can afford to sit on this one. It will never make me rich but I am counting on a nice profit down the road and a fun ride along the way.

Recs

0
Member Avatar MrMonopoly (29.84) Submitted: 3/15/2014 7:52:00 PM : Outperform Start Price: $9.77 OPK Score: -1.14

CEO and serial monopolist Phillip Frost is buying like there is no tomorrow. He seems to know what he is doing, which will allow him to donate to many more music schools and museums when he dies.

Recs

1
Member Avatar YoungNGunnin2 (25.78) Submitted: 3/4/2014 11:00:27 AM : Outperform Start Price: $9.50 OPK Score: +3.07

Insider and Institutional ownership looks great. CEO purchases upwards of 15,000 shares every day like an animal which adds volume and liquidity. Orphan drug not a huge deal, but offers benefits nonetheless. Prostate testing methods should be announced here by the end of the month. Over 21% short float makes for a bull day that could sustain above resistance. Price target of 12.33, I believe it should be higher. I believe I read somewhere there prostate testing method has been being used in Europe but they haven't reported there profits from that? Either way it should be making its debut here in the US in the next few months. Busted out of a slanted double bottom very strongly, and has all its moving averages doing a synchronized dance to their preferred positions. Something major is brewing with the overwhelmingly heavy insider transactions over the past year. His purchases will consistently drive the price up along with little short squeezes in some way shape or form and should be viewed in bullish terms. Humongous pipeline and financials are looking good. Outperform both short and long term.

Recs

0
Member Avatar caelin389 (70.84) Submitted: 2/26/2014 3:27:57 AM : Outperform Start Price: $9.06 OPK Score: +7.19

it moving I bought at 6

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 1/21/2014 3:24:54 AM : Outperform Start Price: $8.69 OPK Score: +11.99

Insiders heavy

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners